PTPRC and central nervous system cancer: Purified tumour cell specimens, which included freshly isolated patient tumour cells from both newly diagnosed and recurrent IDH WT (n = 20) GBM as well as IDH mutant gliomas (n = 10), underwent BH3 profiling and molecular analysis following tissue dissociation and removal of red blood cells (RBCs), myelin and CD45+ cells (Fig. 1A).